Feasibility and safety of pancreatic islet transplantation in the liver by portal vein catheterization using the transjugular route [1]

Transplantation

Volumn 81, Issue 8, 2006, Pages 1220-1221

  Conget, Ignacio ^a,b   Piquer, Sandra ^a   Julià, Marta ^a   Gomis, Ramón ^a   Esmatjes, Enric ^a   García Pagán, Juan Carlos ^a   Bosch, Jaume ^a   Gilabert, Rosa ^a   Ricart, Maria Jose ^a   Fernández Cruz, Laureano ^a   Manyalich, Marti ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Endocrinology and Diabetes Unit   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BLEEDING; CASE REPORT; CATHETERIZATION; DOPPLER ECHOGRAPHY; FEASIBILITY STUDY; FEMALE; FLUOROSCOPY; GRAFT FAILURE; HUMAN; LETTER; LIVER; PANCREAS ISLET TRANSPLANTATION; PORTAL VEIN BLOOD PRESSURE; PORTAL VEIN CATHETERIZATION; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SAFETY;

CATHETERIZATION; FEMALE; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; JUGULAR VEINS; LIVER; MIDDLE AGED; PORTAL VEIN;

EID: 33646803804     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000203297.95946.c6     Document Type: Letter

References (11)

1. Gaglia JL, Shapiro AM, Weir GC. Islet transplantation: progress and challenge. Arch Med Res 2005; 36: 273-280.
2. Robertson RP. Islet transplantation as a treatment for diabetes - a work in progress. N Engl J Med 2004; 350: 694-705.
3. Korsgren O, Nilsson B, Berne C, et al. Current status of clinical islet transplantation. Transplantation 2005; 79: 1289-1293.
4. Hirshberg B, Rother KI, Digon BJ, III, et al. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care 2003; 26: 3288-3295.
5. Venturini M, Angeli E, Maffi P, et al. Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US. Radiology 2005; 234: 617-624.
6. Somberg KA, Lake JR, Tomlanovich SJ, et al. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995; 21: 709-716.
7. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
8. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114: 1296-1303.
9. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069.
10. Villiger P, Ryan EA, Owen R, et al. Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am J Transplant 2005; 5: 2992-2998.
11. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for Trends Pharmacol Sci: results of a randomized study. Gastroenterology 2004; 126: 469-475.